专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

DK67121C 未知
公开(公告)号：DK67121C
公开(公告)日：1948-06-28
申请号：DK33745
申请日：1945-02-09
申请人： PETERSEN LARS CHRISTIAN THORKI
发明人： PETERSEN LARS CHRISTIAN THORKI

2. 发明申请

WO2012001087A1 ANTIBODIES THAT ARE CAPABLE OF SPECIFICALLY BINDING TISSUE FACTOR PATHWAY INHIBITOR 审中-公开
标题翻译：具有特异性结合组织因子途径抑制剂的抗体
公开(公告)号：WO2012001087A1
公开(公告)日：2012-01-05
申请号：PCT/EP2011/060980
申请日：2011-06-30
申请人： NOVO NORDISK A/S , HILDEN, Ida , CLAUSEN, Jes Thorn , PETERSEN, Lars Christian , SØRENSEN, Brit Binow , PETERSEN, Helle Heibroch
发明人： HILDEN, Ida , CLAUSEN, Jes Thorn , PETERSEN, Lars Christian , SØRENSEN, Brit Binow , PETERSEN, Helle Heibroch
IPC分类号： C07K16/38 , A61K39/395 , A61P7/04
CPC分类号： C07K16/28 , A61K39/395 , C07K16/38 , C07K2317/34 , C07K2317/76
摘要： The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.
摘要翻译：本发明涉及能够特异性结合组织因子途径抑制剂（TFPI），中和游离TFPI并降低血液凝血时间的抗体。此外，本发明涉及编码这种抗体的多核苷酸以及包含多核苷酸或表达本发明的抗体的细胞。这样的抗体可用于治疗具有凝血病的受试者，单独和与第二药剂组合。

3. 发明申请

WO2004064870A8 RADIOLABELLED TISSUE FACTOR BINDING AGENT AND THE USE THEREOF 审中-公开
标题翻译：放射性组织因子结合剂及其用途
公开(公告)号：WO2004064870A8
公开(公告)日：2004-11-04
申请号：PCT/DK2004000041
申请日：2004-01-22
申请人： NOVO NORDISK AS , H S RIGSHOSPITALET , HESSE BIRGER , KJAER ANDREAS , STENNICKE HENNING RALF , BJOERN SOEREN E , PETERSEN LARS CHRISTIAN
发明人： HESSE BIRGER , KJAER ANDREAS , STENNICKE HENNING RALF , BJOERN SOEREN E , PETERSEN LARS CHRISTIAN
IPC分类号： A61K51/08 , C12N9/64
CPC分类号： A61K51/088 , C12N9/6437 , C12Y304/21021
摘要： This invention relates to novel compounds, which bind to tissue factor and the use thereof for diagnostic markers. The invention also relates to pharmaceutical compositions comprising the novel compounds as well as their use in the diagnosing, prophylaxis or treatment of diseases or disorders relates to pathobiology involving tissue factor (TF) including bleedings, cancer, inflammation, atherosclerosis and ischemia/reperfusion. Radiolabelled TF agonists may be valuable for diagnostic imaging with a gamma camera, a PET camera or a PET/CT camera, in particular for the evaluation of TF expression of tumor cells, for grading the malignancy of tumor cells known to express TF receptors, for the monitoring of tumors with TF expression during conventional chemotherapy or radiation therapy. Also TF agonists and/or TF antagonists labelled with alpha or beta-emitting isotopes could be used for therapy, possibly with bi-specific binding to compounds with chemotherapeutic action, which may be related tp the presence of TF receptors.

4. 发明申请

WO02096938A2 HUMAN KUNITZ-TYPE PROTEASE INHIBITOR 审中-公开
标题翻译：人类昆虫型蛋白酶抑制剂
公开(公告)号：WO02096938A2
公开(公告)日：2002-12-05
申请号：PCT/DK0200372
申请日：2002-05-31
申请人： NOVO NORDISK AS , JOERGENSEN MARIANNE ULRICH , BANG SUSANNE , OLSEN OLE HVILSTED , PETERSEN LARS CHRISTIAN
发明人： JOERGENSEN MARIANNE ULRICH , BANG SUSANNE , OLSEN OLE HVILSTED , PETERSEN LARS CHRISTIAN
IPC分类号： A61K38/00 , C07K14/81 , C07K14/00
CPC分类号： C07K14/8114 , A61K38/00
摘要： The present invention relates to novel human kunitz-type protease inhibitors as well as polynucleotide constructs encoding such inhibitors, vectors and host cells comprising and expressing the inhibitors, pharmaceutical compositions, uses and methods of treatment.
摘要翻译：本发明涉及新型人类kunitz型蛋白酶抑制剂以及编码这种抑制剂的多核苷酸构建体，载体和宿主细胞，其包含并表达抑制剂，药物组合物，用途和治疗方法。

5. 发明申请

WO1997049684A1 FACTOR VII-BINDING REAGENT 审中-公开
标题翻译：因子VII结合试剂
公开(公告)号：WO1997049684A1
公开(公告)日：1997-12-31
申请号：PCT/DK1997000275
申请日：1997-06-23
申请人： NOVO NORDISK A/S , PETERSEN, Lars, Christian , OLSEN, Ole, Hvilsted , RICHTER, Stefan, Lutz , JAKOBSEN, Palle
发明人： NOVO NORDISK A/S
IPC分类号： C07D231/14
CPC分类号： C07D241/52 , A61K31/16 , A61K31/415 , A61K31/4192 , A61K31/4439 , A61K31/4745 , A61K31/498 , A61K33/30 , C07D231/14 , A61K2300/00
摘要： Compounds of general formula (Ib) wherein X is a chain, aliphatic or comprising hetero atoms as chain members; and R1 is hydrogen, an amino group (optionally substituted with methyl), or a methyl group; and R2 is hydrogen, or a methyl group; or X, in combination with C2, R1, R2, N1, and C3, forms a carbocyclic or heterocyclic system; and wherein the distance between C1 and C3 is from about 0.37 nm to about 0.77, e.g. about 0.57 nm to about 0.67 nm; and pharmaceutically acceptable salts thereof; are zinc chelating agents. The compounds show anticoagulant properties due to an inhibitory interaction with factor VII and serum level Zn . The zinc chelating agents bind to factor VIIa and induces replacement of calcium ions with zinc ions in the serine protease domain of factor VIIa, thereby inhibiting the activity of factor VIIa or tissue factor-factor VIIa complex. The compounds are useful for the treatment of deficiencies of blood clotting factors or the effects of inhibitors to blood clotting factors. Methods for inhibiting clotting activity are disclosed.
摘要翻译：通式（Ib）的化合物，其中X是链，脂族或包含杂原子作为链成员; 和R 1是氢，氨基（任选被甲基取代）或甲基; 和R2是氢或甲基; 或X与C2，R1，R2，N1和C3组合形成碳环或杂环体系; 并且其中C1和C3之间的距离为约0.37nm至约0.77，例如约0.57nm至约0.67nm; 及其药学上可接受的盐; 是锌螯合剂。由于与因子VII和血清水平Zn 2+的抑制相互作用，化合物显示出抗凝血性质。锌螯合剂与因子VIIa结合并诱导因子VIIa的丝氨酸蛋白酶结构域中的锌离子替代钙离子，从而抑制因子VIIa或组织因子因子VIIa复合物的活性。该化合物可用于治疗凝血因子的缺陷或抑制剂对凝血因子的作用。公开了抑制凝血活性的方法。

6. 发明申请

WO1994027631A1 MODIFIED FACTOR VII 审中-公开
标题翻译：修改因子七
公开(公告)号：WO1994027631A1
公开(公告)日：1994-12-08
申请号：PCT/US1994005779
申请日：1994-05-23
申请人： ZYMOGENETICS, INC. , NOVO NORDISK A/S , BERKNER, Kathleen, L. , PETERSEN, Lars, Christian , HART, Charles, E.
发明人： ZYMOGENETICS, INC. , NOVO NORDISK A/S
IPC分类号： A61K37/46
CPC分类号： C12N9/6437 , A61K38/00 , C12Y304/21021
摘要： The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modification render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
摘要翻译：因子VII的催化活性位点被修饰以产生有效中断凝血级联的化合物。该修饰使因子VIIa基本上不能激活血浆因子X或IX。修饰的因子VII的药物组合物用于治疗各种凝血相关疾病。

7. 发明申请

WO1993014123A1 A NOVEL HUMAN KUNITZ-TYPE PROTEASE INHIBITOR AND VARIANTS THEREOF 审中-公开
标题翻译：新型人类昆虫型蛋白酶抑制剂及其变体
公开(公告)号：WO1993014123A1
公开(公告)日：1993-07-22
申请号：PCT/DK1993000006
申请日：1993-01-07
申请人： NOVO NORDISK A/S , NORRIS, Fanny , NORRIS, Kjeld , BJORN, Soren, Erik , PETERSEN, Lars, Christian , OLSEN, Ole, Hvilsted , FOSTER, Donald, Cameron , SPRECHER, Cindy, Ann
发明人： NOVO NORDISK A/S
IPC分类号： C07K07/10
CPC分类号： C07K14/8114 , A61K38/00
摘要： Human Kunitz-type protease inhibitor comprising the following amino acid sequence Leu Pro Asn Val Cys Ala Phe Pro Met Glu Lys Gly Pro Cys Gln Thr Tyr Met Thr Arg Trp Phe Phe Asn Phe Glu Thr Gly Glu Cys Glu Leu Phe Ala Tyr Gly Gly Cys Gly Gly Asn Ser Asn Asn Phe Leu Arg Lys Glu Lys Cys Glu Lys Phe Cys Lys Phe Thr (SEQ ID No. 1) or a variant thereof with protease inhibitor properties.
摘要翻译：包含以下氨基酸序列的人Kunitz型蛋白酶抑制剂Leu Pro Asn Val Cys Ala Phe Pro Met Glu Lys Gly Pro Cys Gln Thr Tyr Met Thr Arg Trp Phe Phe Asn Phe Glu Thr Gly Glu Cys Glu Leu Phe Ala Tyr Gly Gly Cys Gly Gly Asn Ser Asn Asn Phe Leu Arg Lys Glu Lys Cys Glu Lys Phe Cys Lys Phe Thr（SEQ ID No.1）或其具有蛋白酶抑制剂性质的变体。

8. 发明申请

WO1989010374A1 APROTININ ANALOGUES AND A PROCESS FOR THE PRODUCTION THEREOF 审中-公开
标题翻译： APROTININ类似物及其生产工艺
公开(公告)号：WO1989010374A1
公开(公告)日：1989-11-02
申请号：PCT/DK1989000096
申请日：1989-04-25
申请人： NOVO-NORDISK A/S , NORRIS, Kjeld , PETERSEN, Lars, Christian
发明人： NOVO-NORDISK A/S
IPC分类号： C07K07/10
CPC分类号： C07K14/8117 , A61K38/00
摘要： Novel aprotinin analogues having a selected inhibition profile against serine proteases.

9. 发明申请

WO2011023785A1 TARGETING TISSUE FACTOR TO ACTIVATED PLATELETS 审中-公开
标题翻译：针对活化板的组织要素
公开(公告)号：WO2011023785A1
公开(公告)日：2011-03-03
申请号：PCT/EP2010/062519
申请日：2010-08-26
申请人： NOVO NORDISK A/S , HILDEN, Ida , PETERSEN, Lars, Christian , BREINHOLT, Jens , ANDERSEN, Mette, Dahl , BJELKE, Jais, Rose , EGEBJERG, Thomas
发明人： HILDEN, Ida , PETERSEN, Lars, Christian , BREINHOLT, Jens , ANDERSEN, Mette, Dahl , BJELKE, Jais, Rose , EGEBJERG, Thomas
IPC分类号： C07K14/745 , C07K16/46 , A61K38/36 , A61K39/395
CPC分类号： C07K16/2803 , A61K38/00 , C07K14/745 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/64 , C07K2317/92 , C07K2319/33
摘要： The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.
摘要翻译：本发明涉及促凝血融合蛋白，编码所述融合蛋白的多核苷酸和表达所述融合蛋白的细胞。此外，本发明涉及用作药物的融合蛋白。具有凝血病的个体，例如具有或不具有抑制剂的血友病A和B，可用本发明的融合蛋白进行治疗。

10. 发明申请

WO1993014121A1 A HUMAN KUNITZ-TYPE PROTEASE INHIBITOR VARIANT 审中-公开
标题翻译：人类昆虫型蛋白酶抑制剂变种
公开(公告)号：WO1993014121A1
公开(公告)日：1993-07-22
申请号：PCT/DK1993000004
申请日：1993-01-07
申请人： NOVO NORDISK A/S , NORRIS, Fanny , NORRIS, Kjeld , BJORN, Soren, Erik , PETERSEN, Lars, Christian , OLSEN, Ole, Hvilsted
发明人： NOVO NORDISK A/S
IPC分类号： C07K07/10
CPC分类号： C07K14/8114 , A61K38/00
摘要： Variant of human Kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI), the variant comprising the following amino acid sequence X Asp Phe Cys Phe Leu Glu Glu Asp X Gly X Cys X X X X X X Tyr Phe Tyr Asn Asn Gln Thr Lys Gln Cys Glu Arg Phe X Tyr Gly Gly Cys X X X Met Asn Asn Phe X Thr Leu Glu Glu Cys Lys Asn Ile Cys Glu Asp X (SEQ ID No. 1), wherein X represents H or 1-5 naturally occurring amino acid residues except Cys, X -X each independently represents a naturally occurring amino acid residue, and X represents OH or 1-5 naturally occurring amino acid residues except Cys, with the proviso that at least one of the amino acid residues X -X is different from the corresponding amino acid residue of the native sequence.
摘要翻译：人类Kunitz型蛋白酶抑制剂结构域II的组织因子途径抑制剂（TFPI）的变体，包含以下氨基酸序列的变体X 1 Asp Phe Cys Phe Leu Glu Glu Asp X 2 Gly X 3 Cys X X 5 X 6 X 7 X 8 Tyr Phe Tyr Asn Asn Gln Thr Lys Gln Cys Glu Arg Phe X 10 Tyr Gly Gly Cys X 11 X < 12> X 13 Met Asn Asn Phe X 14 Thr Leu Glu Glu Cys Lys Asn Ile Cys Glu Asp X 15（SEQ ID No.1），其中X 1表示H或1-5天然存在除Cys之外的氨基酸残基，X 2 -X 14各自独立地表示天然存在的氨基酸残基，X 15表示除Cys之外的OH或1-5个天然存在的氨基酸残基，条件是至少氨基酸残基X 1 -X 15之一与天然序列的相应氨基酸残基不同。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式